name: Traveler's Diarrhea
category: Infectious
disease_term:
  preferred_term: traveler's diarrhea
  term:
    id: MONDO:0001673
    label: diarrheal disease
parents:
  - Infectious diarrhea
  - Travel-related infections
infectious_agent:
  - name: Enterotoxigenic Escherichia coli
    infectious_agent_term:
      preferred_term: Enterotoxigenic Escherichia coli
      term:
        id: NCBITaxon:562
        label: Escherichia coli
pathophysiology:
  - name: Ingestion of contaminated food or water during travel
    description: Travelers ingest enteric pathogens through unsafe food and water, initiating diarrheal illness.
    locations:
      - preferred_term: gastrointestinal tract
        term:
          id: UBERON:0005409
          label: gastrointestinal tract
    evidence:
      - reference: PMID:35839362
        supports: SUPPORT
        snippet: Infectious noninflammatory diarrhea is often viral in etiology and is the most common presentation; however, bacterial causes are also common and may be related to travel or foodborne illness.
        explanation: Acute diarrhea review links bacterial diarrheal illness to travel and foodborne exposures.
  - name: ETEC adherence via colonization factors
    description: Enterotoxigenic E. coli use colonization factors to adhere to intestinal epithelium and establish infection.
    locations:
      - preferred_term: small intestine
        term:
          id: UBERON:0002108
          label: small intestine
    evidence:
      - reference: PMID:38052687
        supports: SUPPORT
        snippet: Colonization factors (CFs) are major virulence factors of enterotoxigenic Escherichia coli (ETEC).
        explanation: Review highlights CFs as key adherence determinants enabling ETEC intestinal colonization.
  - name: Enterotoxin-driven secretory diarrhea
    description: ETEC heat-labile and heat-stable enterotoxins bind epithelial receptors, driving chloride and water secretion and watery diarrhea.
    locations:
      - preferred_term: small intestine
        term:
          id: UBERON:0002108
          label: small intestine
    evidence:
      - reference: PMID:35358002
        supports: SUPPORT
        snippet: ETEC is characterized by the ability to produce major virulence factors including colonization factors (CFs) and enterotoxins, that bind to specific receptors on epithelial cells and induce diarrhea.
        explanation: Review notes ETEC enterotoxins trigger receptor-mediated fluid secretion leading to diarrhea.
phenotypes:
  - name: Acute watery diarrhea
    description: Sudden onset of loose, watery stools during or shortly after travel.
    phenotype_term:
      preferred_term: Diarrhea
      term:
        id: HP:0002014
        label: Diarrhea
    evidence:
      - reference: PMID:35358002
        supports: SUPPORT
        snippet: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in children and travelers in developing countries.
        explanation: Establishes diarrhea as the hallmark symptom of ETEC-associated traveler's diarrhea.
  - name: Abdominal cramps
    description: Cramping pain accompanying diarrhea.
    phenotype_term:
      preferred_term: Abdominal pain
      term:
        id: HP:0002027
        label: Abdominal pain
    evidence:
      - reference: PMID:35839362
        supports: PARTIAL
        snippet: History for patients with acute diarrhea should include onset and frequency of symptoms, stool character, a focused review of systems including fever and other symptoms, and evaluation of exposures and risk factors.
        explanation: Guidance for acute diarrhea evaluation highlights associated abdominal symptoms that accompany diarrheal illness.
  - name: Nausea
    description: Feeling of sickness often preceding or accompanying diarrhea.
    phenotype_term:
      preferred_term: Nausea
      term:
        id: HP:0002018
        label: Nausea
    evidence:
      - reference: PMID:35839362
        supports: PARTIAL
        snippet: Acute diarrheal disease accounts for 179 million outpatient visits annually in the United States... History for patients with acute diarrhea should include onset and frequency of symptoms, stool character, a focused review of systems including fever and other symptoms.
        explanation: Clinical review notes nausea and systemic symptoms are routinely assessed with acute diarrheal illnesses.
treatments:
  - name: Oral rehydration therapy
    description: Fluid and electrolyte replacement is the cornerstone of treatment.
    treatment_term:
      preferred_term: fluid replacement therapy
      term:
        id: MAXO:0000618
        label: fluid replacement therapy
    evidence:
      - reference: PMID:35839362
        supports: SUPPORT
        snippet: In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration.
        explanation: Review emphasizes oral rehydration as first-line management for acute diarrheal illness.
  - name: Loperamide
    description: Antimotility agent for symptomatic relief in non-invasive cases.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: loperamide hydrochloride
            term:
              id: NCIT:C62046
              label: Loperamide Hydrochloride
    evidence:
      - reference: PMID:39453259
        supports: PARTIAL
        snippet: |
          Knowledge gaps persisted: over 50% were unaware of TD's self-limited nature, 30% did not recognize loperamide as a symptom reliever, and 36% believed all travelers should take antibiotics to prevent TD.
        explanation: Pre-travel consultation study identifies loperamide as a recognized symptomatic reliever for traveler's diarrhea.
  - name: Fluoroquinolone antibiotics
    description: Empiric antibiotic therapy for moderate to severe cases.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: ciprofloxacin
            term:
              id: NCIT:C376
              label: Ciprofloxacin
    evidence:
      - reference: PMID:35839362
        supports: PARTIAL
        snippet: Empiric antibiotics are rarely warranted, except in sepsis and some cases of travelers' or inflammatory diarrhea. Targeted antibiotic therapy may be appropriate following microbiologic stool assessment.
        explanation: Clinical review notes selective use of antibiotics, including in some traveler's diarrhea cases.
      - reference: PMID:40024692
        supports: PARTIAL
        snippet: Resistant strains to representative therapeutic agents such as ciprofloxacin and azithromycin have been reported in recent years, and multidrug-resistant ETEC has also emerged.
        explanation: Resistance trends in ETEC underscore reserving fluoroquinolones for indicated cases and adjusting based on susceptibility.
  - name: Rifaximin
    description: Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: rifaximin
            term:
              id: NCIT:C95262
              label: rifaximin
    evidence:
      - reference: PMID:32966000
        supports: SUPPORT
        snippet: Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers’ diarrhea caused by noninvasive strains of Escherichia coli.
        explanation: StatPearls entry lists rifaximin as indicated for traveler's diarrhea from noninvasive E. coli.
      - reference: PMID:36221413
        supports: PARTIAL
        snippet: Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63).
        explanation: Network meta-analysis shows rifaximin reduces traveler’s diarrhea incidence more than probiotics, supporting its preventive use.
  - name: Bismuth subsalicylate
    description: Bismuth-based agent for symptom control and prophylaxis of traveler’s diarrhea.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: bismuth subsalicylate
            term:
              id: NCIT:C333
              label: Bismuth Subsalicylate
    evidence:
      - reference: PMID:32809532
        supports: PARTIAL
        snippet: This educational activity focuses on bismuth subsalicylate's applications in managing gastrointestinal discomfort and traveler's diarrhea.
        explanation: StatPearls review describes bismuth subsalicylate use for managing traveler's diarrhea symptoms.
      - reference: PMID:33064636
        supports: PARTIAL
        snippet: The antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea.
        explanation: Narrative review highlights bismuth’s multimodal activity for diarrheal symptom relief, including traveler’s diarrhea.
  - name: Probiotic prophylaxis
    description: Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:38458507
        supports: SUPPORT
        snippet: Based on this systematic review and meta-analysis, specific probiotic strains, including L. acidophilus, L. rhamnosus, L. fermentum, S. cerevisiae, and S. boulardii, may prevent TD.
        explanation: Meta-analysis finds several probiotic strains reduce risk of traveler's diarrhea, supporting prophylactic use.
      - reference: PMID:36221413
        supports: SUPPORT
        snippet: Both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95).
        explanation: Network meta-analysis quantifies reduced traveler’s diarrhea incidence with probiotic prophylaxis.
  - name: Education on safe food and water practices
    description: Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
    evidence:
      - reference: PMID:39453259
        supports: PARTIAL
        snippet: The EG/post-consultation group showed significant improvement in knowledge, with correct answers increasing from 63% to 75%... knowledge gaps persisted... indicating the need for targeted interventions to increase travelers' literacy and optimize pre-travel consultations.
        explanation: Study shows pre-travel counseling improves knowledge about traveler’s diarrhea prevention, underscoring value of education.
      - reference: PMID:40035303
        supports: PARTIAL
        snippet: Traveling abroad carries the risk of traveler's diarrhea, which affects 20 to 50% of individuals. This article focuses on the definition, classification, epidemiology, etiology, prevention, and treatment management of traveler's diarrhea. It also describes recommendations for patients traveling to higher-risk areas, which can be used by pharmacists in counceling activities in the pharmacy.
        explanation: Pharmacy guidance resource supports counseling travelers on prevention and treatment choices.
  - name: Rifaximin prophylaxis
    description: Prophylactic rifaximin to reduce incidence of traveler’s diarrhea in high-risk itineraries with noninvasive E. coli exposure.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: rifaximin
            term:
              id: NCIT:C95262
              label: rifaximin
    evidence:
      - reference: PMID:36221413
        supports: SUPPORT
        snippet: Compared with placebo, both probiotics and rifaximin were associated with lower incidence of TD (probiotics, RR 0.85, 95% CI 0.76-0.95; rifaximin, RR 0.47, 95% CI 0.35-0.63), and rifaximin was more effective than probiotics (RR 0.56, 95% CI 0.4-0.78).
        explanation: Network meta-analysis shows rifaximin prophylaxis significantly reduces traveler’s diarrhea incidence compared with placebo and probiotics.
differential_diagnoses:
  - name: Campylobacter enteritis
    description: Common bacterial cause of traveler’s diarrhea presenting with febrile inflammatory diarrhea.
    distinguishing_features:
      - Often associated with undercooked poultry or unpasteurized milk exposure.
      - May present with fever and dysentery rather than purely watery stools.
    disease_term:
      preferred_term: campylobacteriosis
      term:
        id: MONDO:0005688
        label: campylobacteriosis
    evidence:
      - reference: PMID:30725718
        supports: SUPPORT
        snippet: Campylobacter organisms are also a significant cause of traveler's diarrhea, particularly in Thailand and other areas of Southeast Asia.
        explanation: StatPearls review identifies Campylobacter as a major cause of traveler's diarrhea, supporting differential consideration.
  - name: Giardiasis
    description: Parasitic infection causing prolonged watery diarrhea and malabsorption that can be acquired during travel.
    distinguishing_features:
      - Exposure to untreated freshwater or contaminated water during travel.
      - Prolonged diarrhea with bloating and flatulence; stool antigen tests positive for Giardia.
    disease_term:
      preferred_term: giardiasis
      term:
        id: MONDO:0001103
        label: giardiasis
    evidence:
      - reference: PMID:30020611
        supports: SUPPORT
        snippet: Giardiasis... is one of the most common treatable causes of gastroenteritis worldwide... risk factors for giardiasis include international travel... The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating.
        explanation: StatPearls entry links giardiasis to travel exposure and diarrheal presentation, supporting its role as a differential.
environmental:
  - name: High-risk travel with contaminated food and water exposure
    description: Travel to regions with unsafe food and water increases risk of bacterial TD and acquisition of resistant E. coli.
    evidence:
      - reference: PMID:36180932
        supports: PARTIAL
        snippet: The overall pooled attack rate of TD was 39%... There were significant risks to be colonized with ESBL-EC among the travelers who experienced TD.
        explanation: Meta-analysis shows high TD attack rates and resistant E. coli colonization among travelers, highlighting contaminated food and water risks during travel.
datasets: []
